Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

This study is currently recruiting participants.

Verified by Alcon Research, February 2008

First Received: April 17, 2006 Last Updated: February 29, 2008 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00315640

Purpose

The purpose of this trial is to study the safety, efficacy, and duration of effect of anecortave acetate for the treatment of elevated IOP following intravitreal triamcinolone acetonide therapy.

Condition	Intervention	Phase
Eye Diseases	Drug: Anecortave Acetate	Phase II

MedlinePlus related topics: Eye Diseases

Drug Information available for: Anecortave acetate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Mean IOP [ Time Frame: Duration ]

Estimated Enrollment:	60
Study Start Date:	December 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Either gender
18 years of age or older
IOP elevation caused by steroid usage

Exclusion Criteria:

Under 18 years of age

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00315640

Contacts

Contact: Alcon Call Center

888-451-3937

Locations

United States, Florida
Jacksonville	Recruiting
Jacksonville, Florida, United States, 32204
Miami	Recruiting
Miami, Florida, United States, 33136
United States, Michigan
Detroit	Recruiting
Detroit, Michigan, United States, 48202
United States, Texas
	Recruiting
Fort Worth, Texas, United States, 76134
Contact: Alcon Call Center 888-451-3937
Houston	Recruiting
Houston, Texas, United States, 77030
Brazil
San Paulo	Recruiting
San Paulo, Brazil
Hungary
Budapest	Recruiting
Budapest, Hungary
Italy
Padova	Recruiting
Padova, Italy
Netherlands
Amsterdam	Recruiting
Amsterdam, Netherlands
Puerto Rico
Bayamon	Recruiting
Bayamon, Puerto Rico, 00961
Spain
Barcelona	Recruiting
Barcelona, Spain
United Kingdom
Newcastle upon Tyne	Recruiting
Newcastle upon Tyne, United Kingdom

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Theresa Landry

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-05-03, 2005-001598-93
Study First Received:	April 17, 2006
Last Updated:	February 29, 2008
ClinicalTrials.gov Identifier:	NCT00315640 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Elevated IOP due to intravitreal triamcinolone therapy

Study placed in the following topic categories:

Triamcinolone Acetonide
Eye Diseases
Triamcinolone
Triamcinolone diacetate
Triamcinolone hexacetonide

Additional relevant MeSH terms:

Eye Diseases

ClinicalTrials.gov processed this record on May 07, 2009